Vetter Appoints Managing Director
![](/46/pdcnewsitem/03/43/64/saC9uZvN4XT4qeu.jpg)
Vetter has announced that the company’s Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective 1 April 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.
Oliver Albrecht has more than 20 years of experience managing international, medium-sized listed companies both as a Managing Director and as Chief Financial Officer in a wide variety of industries including banking, automotive, and mechanical engineering. In recent years, Oliver held the position as Chief Financial Officer for SHW AG headquartered in Aalen, Germany and acted also as an independent consultant for mid-sized companies.
A seasoned finance and operations executive, Oliver’s previous positions include senior posts at companies including Chief Financial Officer for centrotherm photovoltaics AG and as a Director in the Financial and Banking Sector. He holds a diploma in Business from the University of Mannheim, Germany.
“We undertook a rigorous selection process to identify the right person to help lead our company forward,” said Udo J. Vetter, Chairman of the company’s Advisory Board and member of the owner family. “Oliver’s vast experience in a variety of industries, combined with his deep knowledge of achieving operational and financial excellence will be a tremendous asset to Vetter.”
In his new role as Managing Director, Albrecht will be responsible for two of the eight company divisions, the first of which is comprised of Finance, Controlling and IT. The second division includes Corporate Development, Legal and Corporate Compliance.
Peter Soelkner and Thomas Otto, Vetter’s two Managing Directors added, “we are happy to have this Managing Director position filled with someone having the background that Oliver Albrecht offers. We are pleased to assist our new colleague in any way possible to make his start at Vetter both promising and productive. We wish him success in his new position.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance